Pacific Edge is a global cancer diagnostics company leading the way in the development and commercialisation of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease.
Our products are built from our proprietary genetic databases, which are used to identify diagnostic and prognostic biomarkers for cancer.
Our intellectual property covers the areas of bladder, gastric, colorectal and endometrial cancers and melanoma; however, our commercial focus is on bladder cancer products for the short to medium term. Our wider portfolio is expected to provide us with further options in the future.
Cxbladder is a next generation genomic biomarker test for the detection and surveillance of bladder cancer. The test is non-invasive, highly effective and more accurate than other urine-based cancer tests.
Cxbladder offers a step change in how bladder cancer is detected and monitored, improving standard of care. The Cxbladder suite has been designed to meet unmet clinical needs along the patient care pathway.
Our Business Model
We operate a franchise-like business model, which includes our wholly owned subsidiaries and other licensed partners.
We have targeted specific geographies and markets where we expect our products can be readily adopted at scale.
Pacific Edge has certified laboratories in New Zealand and in the United States.
Both laboratories hold a Certificate of Compliance from the Center for Medicare & Medicaid Services (CMS) for Clinical Laboratory Improvement Amendments (CLIA), which sets the standards for clinical laboratory testing in the United States.
This compliance enables Pacific Edge's laboratories to provide commercial services to clinicians and process urine samples from patients in the United States for Cxbladder.